Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Mylan stock | US$16.355
Own your own MYL shares in just a few minutes.
Fact checked
US$16.355
current price
current price
US$-0.065
change
change
-0.396%
change %
change %
How to buy stocks in Mylan
- Compare share trading platforms.To buy shares in a US company from Canada you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees. Narrow down some brokers with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Mylan. Find the share by name or ticker symbol: MYL. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Mylan reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of US$16.355, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Mylan, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Mylan. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Price details for Mylan (MYL)
| Open | $16.21 | Previous close | $16.42 |
| High | $16.42 | Change | $-0.065 |
| Low | $16.005 | Change % | -0.396% |
| Close | $16.355 | Timestamp | 1596830400 |
| Volume | N/A | GMT offset | 0 |
Mylan stock price
Use our graph to track the performance of MYL stocks over time.Compare online trading platforms
This is not a recommendation, it represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Mylan company summary
Information last updated 2020-08-04.
Mylan (MYL) is a leading Pharmaceuticals business based in the USA. Mylan (MYL) is listed on the NASDAQ and employs 35000 staff.
Profile
| Industry | Drug Manufacturers—Specialty & Generic | Currency symbol | $ |
| Code | MYL | Country name | USA |
| Type | Common Stock | Country ISO | US |
| Name | Mylan, Inc | ISIN | NL0011031208 |
| Exchange | NASDAQ | CUSIP | 628530107 |
| Currency code | USD | Sector | Healthcare |
| Currency name | US Dollar | Full-time employees | 35000 |
Detailed company information
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Disclaimer: This information provided is general in nature only and does not take into account your personal objectives, financial situation or needs. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore is not appropriate for all investors. Past performance is not an indication of future results. Seek professional advice and consider your own personal circumstances before making any decision based on this information.